Rudolf C. Hergesheimer
Tours, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Intrabody B1 targeting TDP-43 modulates neuroinflammatory and metabolic pathways in a preclinical ALS model.
Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Published: April 17, 2026
Targeted mRNA Delivery Using Bispecific Antibody-Lipid Nanoparticle Complexes.
Journal: Molecular pharmaceutics
Published: February 20, 2026
TAR DNA-binding protein of 43 kDa (TDP-43) and amyotrophic lateral sclerosis (ALS): a promising therapeutic target.
Journal: Expert opinion on therapeutic targets
Published: June 02, 2022
TDP43 aggregates: the 'Schrödinger's cat' in amyotrophic lateral sclerosis.
Journal: Nature reviews. Neuroscience
Published: June 09, 2021
Behavioral, Hormonal, Inflammatory, and Metabolic Effects Associated with FGF21-Pathway Activation in an ALS Mouse Model.
Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Published: September 15, 2020
Conditioned Medium from Cells Overexpressing TDP-43 Alters the Metabolome of Recipient Cells.
Journal: Cells
Published: July 17, 2020
Understanding and managing metabolic dysfunction in Amyotrophic Lateral Sclerosis.
Journal: Expert review of neurotherapeutics
Published: June 26, 2020
Advances in disease-modifying pharmacotherapies for the treatment of amyotrophic lateral sclerosis.
Journal: Expert opinion on pharmacotherapy
Published: April 04, 2020
Aβ1-42 and Tau as Potential Biomarkers for Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis.
Aβ1-42 and Tau as Potential Biomarkers for Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis.
Journal: International journal of molecular sciences
Published: March 04, 2020
Last Updated: 09/26/2026